Search

Displaying results 7031 - 7040 of 7067 in total
  1. Drug

    Oxalic Acid

    go.drugbank.com/drugs/DB03902
    Experimental

    A strong dicarboxylic acid occurring in many plants and vegetables. It is produced in the body by metabolism of glyoxylic acid or ascorbic acid. It is not metabolized but excreted in the urine.

    Categories: Compounds used in a research, industrial, or household setting
  2. Drug

    Inosine

    go.drugbank.com/drugs/DB04335
    Approved

    A purine nucleoside that has hypoxanthine linked by the N9 nitrogen to the C1 carbon of ribose.

    Synonyms: hypoxanthine D-riboside, 9-β-D-ribofuranosylhypoxanthine
  3. Drug

    Afimoxifene

    go.drugbank.com/drugs/DB04468
    Investigational

    Afimoxifene (4-Hydroxytamoxifen, trade name TamoGel) is a new estrogen inhibitor under investigation for a variety of estrogen-dependent conditions, including cyclic breast pain and gynecomastia.

  4. Drug

    Estrone sulfate

    go.drugbank.com/drugs/DB04574
    Approved

    Estrone sulfate (as estropipate) is a form of estrogen.

  5. Drug

    Quinestrol

    go.drugbank.com/drugs/DB04575
    Approved

    The 3-cyclopentyl ether of ethinyl estradiol.

  6. Drug

    Imazaquin

    go.drugbank.com/drugs/DB04582
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    2,5-di-tert-butylhydroquinone

    go.drugbank.com/drugs/DB04638
    Experimental

    Synonyms: 2,5-di-tert-butylbenzene-1,4-diolCategories: Compounds used in a research, industrial, or household setting
  8. Drug

    Nilotinib

    go.drugbank.com/drugs/DB04868
    ApprovedInvestigational

    Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). … ), another tyrosine kinase inhibitor used as a first-line treatment for CML.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  9. Drug

    Cobimetinib

    go.drugbank.com/drugs/DB05239
    ApprovedInvestigational

    Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been app...

    Categories: UGT2B7 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index
  10. Drug

    Romidepsin

    go.drugbank.com/drugs/DB06176
    ApprovedInvestigational

    Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index